Glenmark Pharmaceuticals Limited (NSE:GLENMARK) announced on 21 August 2026 that its US subsidiary, Glenmark Pharmaceuticals Inc., USA, has launched Calcium Gluconate Injection USP in three presentations, targeting the reference listed drug of Fresenius Kabi USA, LLC under NDA 208418.
Key Highlights
- Glenmark Pharmaceuticals Inc., USA launched Calcium Gluconate Injection USP in 1,000 mg/10 mL and 5,000 mg/50 mL Single-Dose Vials and a 10,000 mg/100 mL Pharmacy Bulk Package.
- The product is bioequivalent and therapeutically equivalent to the reference listed drug of Fresenius Kabi USA, LLC under NDA 208418.
- IQVIA sales data for the 12 months ending June 2026 placed the combined Calcium Gluconate Injection market at approximately USD 69.9 million in annual sales.
- Marc Kikuchi, President and Business Head, North America, cited the launch as part of Glenmark's strategy to build its US injectables and hospital portfolio.
About the Company
Glenmark Pharmaceuticals Limited (NSE:GLENMARK, BSE:532296), headquartered in Mumbai, is a research-led global pharmaceutical company with 11 manufacturing facilities across four continents and six R&D centres. It operates commercially in 80-plus countries, with a portfolio spanning branded generics, innovative medicines, and consumer health products, focused on respiratory, dermatology, and oncology therapy areas.
Announcement in Detail
Glenmark Pharmaceuticals Inc., USA, operating from Elmwood Park, New Jersey, announced the launch of Calcium Gluconate Injection USP on 21 August 2026. The product is available in three presentations: 1,000 mg/10 mL (100 mg/mL) Single-Dose Vials, 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials, and a 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package. The filing confirms bioequivalence and therapeutic equivalence to the Fresenius Kabi USA, LLC reference listed drug under NDA 208418.
According to IQVIA National Sales Perspectives data for the 12-month period ending June 2026, the combined Calcium Gluconate Injection market, including the brand and all available therapeutic equivalents, recorded annual sales of approximately USD 69.9 million. The announcement notes that Glenmark's product is approved only for the indications listed in its own label, which may differ from those of the reference listed drug.
Impact on Investors
Investors will note that this launch adds a new injectable product to Glenmark's US generics portfolio, with the filing showing the addressable market at approximately USD 69.9 million annually per IQVIA data. The disclosed terms do not specify Glenmark's projected market share or revenue contribution from this product, so the financial impact on consolidated results cannot be determined from the announcement alone.
Shareholders will observe that this is a subsidiary-level commercial launch rather than a board or financial resolution, meaning no immediate change to the company's capital structure, dividend policy, or shareholder rights arises from this filing. The announcement indicates continued execution within Glenmark's stated US injectables strategy.
Sector / Market Context
The US generics injectables market remains a priority segment for Indian pharmaceutical exporters. According to the US Food and Drug Administration's ANDA approval data, hospital-use injectables such as calcium gluconate, used in hypocalcaemia and cardiac conditions, represent a category where supply resilience has been a regulatory and procurement focus for US healthcare institutions in recent years.